Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.644
5.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc.
Accounts Payable
Reviva Pharmaceuticals Holdings, Inc.
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
|
Accounts Payable
$8.8m
|
CAGR 3-Years
175%
|
CAGR 5-Years
211%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Payable
$9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Payable
$3.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
3%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Payable
$5.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Payable
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Payable
$2.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
Reviva Pharmaceuticals Holdings, Inc.
Glance View
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.
See Also
What is Reviva Pharmaceuticals Holdings, Inc.'s Accounts Payable?
Accounts Payable
8.8m
USD
Based on the financial report for Sep 30, 2024, Reviva Pharmaceuticals Holdings, Inc.'s Accounts Payable amounts to 8.8m USD.
What is Reviva Pharmaceuticals Holdings, Inc.'s Accounts Payable growth rate?
Accounts Payable CAGR 5Y
211%
Over the last year, the Accounts Payable growth was 66%. The average annual Accounts Payable growth rates for Reviva Pharmaceuticals Holdings, Inc. have been 175% over the past three years , 211% over the past five years .
You don't have any saved screeners yet